Birchview Capital, LP’s Nektar Therapeutics Position
Does Birchview Capital, LP own Nektar Therapeutics (NKTR)? Yes — 31.0K shares worth $2M (+1.27% of its 13F portfolio) as of Q1 2026.
Position Value
$2M
Q1 2026
Shares
31.0K
% of Portfolio
+1.27%
Quarters Held
3
currently held
Position History NKTR
Reported value by quarter
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Birchview Capital, LP’s full portfolio or all institutional holders of NKTR.